Result for
Tag: vaccine effectiveness
June 15, 2021
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
In solid organ transplant recipients, a third dose of a COVID-19 vaccine was not able to elicit detectable anti-SARS-CoV-2 antibody responses in 53% of participants in a cohort study (n=30). Prior to receiving the third dose, 80% of patients did not have detectable antibody responses. All patients were fully vaccinated with mRNA vaccines (57% Pfizer-BioNTech,…
Naturally Enhanced Neutralizing Breadth against SARS-CoV-2 One Year after Infection
82% of individuals recovered from COVID-19 maintained RBD-specific IgG titers, RBD-specific B cells, and neutralizing activities between 6-12 months after infection, according to analysis of 68 recovered individuals, suggesting long-lived immunity to COVID-19. In 41% of participants who received an mRNA vaccine, vaccination increased IgG responses by 30-fold, neutralizing activity by 50-fold, and circulating number…
June 3, 2021
Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
In a systematic review and meta-analysis of 25 randomized trials assessing safety and efficacy of COVID-19 vaccines, mRNA-based (e.g., Pfizer-BioNTech and Moderna) and adenovirus-vectored (e.g., Oxford-AstraZeneca, Johnson & Johnson, Sputnik V) vaccines had the highest efficacy in phase 2/3 trials (94.6% and 80.2%, respectively). The mRNA-based vaccines had the highest level of side effects reported,…
June 1, 2021
Cellular and Humoral Immunogenicity of a SARS-CoV-2 MRNA Vaccine in Patients on Hemodialysis
[Pre-print, not peer-reviewed] In a cohort of patients on intermittent hemodialysis (n=81), the Pfizer-BioNTech vaccine elicited diminished anti-SARS-CoV-2 antibody responses compared to healthy controls (n=34). Plasma and saliva IgG responses and antibody binding to variants of concern were lower in dialysis patients, particularly binding against the B.1.351 variant. Consistent with humoral responses, vaccine-induced cellular immune…
May 20, 2021
Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents
The incidence of SARS-CoV-2 infections among a sample of residents of nursing homes in the US who received an mRNA COVID-19 vaccine (n=18,242, 80% Pfizer-BioNTech vaccine) decreased from 4.5% within 0-14 days after the first dose to 1.4% within 15-28 days after the first dose. Cases occurring 14 or more days after the second dose…